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Abstract
Background: Patients accessing antiretroviral treatment (ART) programmes in sub-Saharan
Africa frequently have very advanced immunodeficiency. Previous data suggest that such patients
may have diminished capacity for CD4 cell count recovery.
Methods: Rates of CD4 cell increase were determined over 48 weeks among ART-naïve
individuals (n = 596) commencing ART in a South African community-based ART programme.
Results: The CD4 cell count increased from a median of 97 cells/µl at baseline to 261 cells/µl at
48 weeks and the proportion of patients with a CD4 cell count <100 cells/µl decreased from 51%
at baseline to just 4% at 48 weeks. A rapid first phase of recovery (0–16 weeks, median rate = 25.5
cells/µl/month) was followed by a slower second phase (16–48 weeks, median rate = 7.7 cells/µl/
month). Compared to patients with higher baseline counts, multivariate analysis showed that those
with baseline CD4 counts <50 cells/µl had similar rates of phase 1 CD4 cell recovery (P = 0.42),
greater rates of phase 2 recovery (P = 0.007) and a lower risk of immunological non-response (P
= 0.016). Among those that achieved a CD4 cell count >500 cells/µl at 48 weeks, 19% had baseline
CD4 cell counts <50 cells/µl. However, the proportion of these patients that attained a CD4 count
200 cells/µl at 48 weeks was lower than those with higher baseline CD4 cell counts.
Conclusion: Patients in this cohort with baseline CD4 cell counts <50 cells/µl have equivalent or
greater capacity for immunological recovery during 48 weeks of ART compared to those with
higher baseline CD4 cell counts. However, their CD4 counts remain <200 cells/µl for a longer
period, potentially increasing their risk of morbidity and mortality in the first year of ART.
Background
The World Health Organisation (WHO) estimated that in
June 2005 4.7 million people living in sub-Saharan Africa
were in urgent need of antiretroviral treatment (ART) [1].
Despite formidable logistical hurdles, the number of indi-
viduals able to access this treatment in the region is
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expanding. One of the programmatic challenges facing
ART services in sub-Saharan Africa is that many HIV-
infected patients only access healthcare once they have
developed advanced symptomatic disease [2] and this
delay may be further compounded by health-systems
delays. The median CD4 cell count among those enrolling
in ART programmes is often under 100 cells/µl even
where programmes have been well established for several
years [3-5].
Patients enrolling into ART programmes with very low
CD4 cell counts have heightened risk of morbidity and
mortality both before and during the initial months of
ART [5-8]. Moreover, advanced pre-treatment immunode-
ficiency is also reported to be associated with diminished
capacity for restoration of CD4 cell counts and CD4 cell
functional responses during ART [9-14]. This raises the
concern that many patients entering ART programmes in
sub-Saharan Africa may have limited potential for
immune recovery. Although previous studies from sub-
Saharan Africa have reported overall CD4 cell count
responses [3,15,16], there are no published data from the
region regarding rates of CD4 cell recovery and rates of
immunological non-response to ART among patients
with CD4 cell <50 cells/µl.
In this study we have examined determinants of CD4 cell
count recovery among patients accessing a community-
based antiretroviral programme in South Africa. We focus
on the hypothesis that advanced pre-treatment immuno-
deficiency diminishes the capacity for CD4 cell count
recovery during ART as determined by rates of CD4 cell
count increase and risk of immunological non-response.
Methods
Study population
We studied patients accessing ART at the Gugulethu Com-
munity Health Centre, Cape Town, South Africa [5]. The
vast majority of patients receiving treatment at this clinic
live in conditions of low socioeconomic status and HIV
transmission is predominantly heterosexual. The South
African national ART programme guidelines are based on
the World Health Organisation (WHO) 2002 recommen-
dations [17], with criteria for ART including those with a
prior AIDS diagnosis (WHO stage 4 disease) or a blood
CD4 cell count <200 cells/µl.
The first-line ART regimen was comprised of stavudine,
lamivudine plus a non-nucleoside reverse transcriptase
inhibitor (efavirenz or nevirapine). The second-line regi-
men for those failing first-line treatment was comprised of
lopinavir/ritonavir, zidovudine and didanosine. Treat-
ment adherence exceeds 90% at one year [18]. All treat-
ment was free of charge and there were no interruptions
in drug supply. All patients with CD4 counts <200 cells/µl
received daily cotrimoxazole prophylaxis; dapsone was
used as an alternative.
Data collection
Plasma HIV-1 load was measured at baseline and 4
monthly during treatment using Versant™ HIV-1 RNA 3.0
branched chain DNA assay (Bayer HealthCare,
Leverkusen, Germany) with a lower limit of detection of
50 RNA copies/ml. Blood CD4 cell counts were measured
at the same time-points by flow cytometry using FACS-
Count™ (Becton Dickinson Inc., Franklin Lakes, NJ, USA).
These assays were all performed in a single nationally
accredited laboratory which has rigorous quality assur-
ance procedures.
Structured clinical and laboratory records were main-
tained on all patients screened on entry to the ART pro-
gramme and this information was transferred on a weekly
basis to a computer database. Data were analysed from
the start of the programme in September 2002 until data
censorship in August 2005. All treatment-naive patients
aged over 15 years and with at least a 16-week follow-up
time point were included in the analysis. Study of these
patients was in compliance with the Declaration of Hel-
sinki and was approved by the Research Ethics Committee
of the University of Cape Town; all patients enrolled gave
written informed consent.
Data analysis
Data were analysed using Stata version 9.0 (College Sta-
tion, Texas, USA). We calculated absolute responses in
CD4 cell counts during three intervals (from baseline to
16 weeks of ART, 16 to 32 weeks, and 32 to 48 weeks), as
well as rates of CD4 cell increase (cells/µl/month) during
each interval. The first interval was used as an estimate of
the initial (phase 1) response to ART. The CD4 cell count
responses observed during the latter two intervals (16 to
32 and 32 to 48 weeks after treatment initiation) were
very similar, and were combined into a single measure of
the second phase of CD4 cell responses (phase 2).
We further evaluated CD4 cell responses in the following
ways: i) whether patients failed to attain an absolute CD4
cell count increase from baseline of at least 50 cells/µl at
48 weeks (defined as immunological non-response); ii)
whether patients achieved an absolute CD4 count of 200
cells/µl at the 48 week visit; iii) and whether patients had
achieved an absolute CD4 cell count of 500 cells/µl at 48
weeks (super-responders).
In bivariate analyses, medians were compared using Wil-
coxon rank-sum and sign-rank tests; proportions were
compared using chi-square tests. All statistical tests were
two-sided at alpha = 0.05. Separate multiple linear regres-
sion models were used to examine factors associated with
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rates of CD4 cell count increase per month during the first
and second phases. Baseline CD4 cell counts were catego-
rised as follows: <50, 50–99, 100–149 and >150 cells/µl.
Multiple logistic regression was used to assess factors asso-
ciated with the binary outcomes of a CD4 cell increase of
≥ 50 cells/µl and ≥ 100 cells/µl during the 48 weeks of
ART, as well as achieving an absolute CD4 cell count of ≥
200 cells/µl during follow-up. Variables were included in
multivariate models if they demonstrated a persistent
association with the outcome of interest, or if their
removal affected appreciably associations involving other
variables [19].
Results
Baseline characteristics and follow-up
Of 698 individuals who commenced ART between Sep-
tember 2002 and April 2005, 596 (85%) had completed a
16-week follow-up visit at the time of data censorship, 34
(5%) were awaiting this appointment, 48 (7%) had died
and 20 (3%) were either transferred out or were lost to fol-
low-up. Of the 596 individuals who met the inclusion cri-
teria for the study, 580 (97%) remained within the
programme at study censorship, 11 (2%) died and 7 (1%)
were lost from the programme.
At baseline the median age was 32 years (IQR, 28–38) and
75% were female. The median plasma viral load was 4.88
log10 RNA copies/ml (IQR, 4.50–5.27) and 58% of
patients had a viral load >100,000 copies/ml. The median
blood CD4 cell count was 97 cells/µl (IQR, 50–153) and
the proportions of patients with CD4 cell counts within
the ranges <50, 50–99, 100–149 and ≥ 150 cells/µl were
25%, 26%, 23% and 26%, respectively. Eighty per cent of
patients had symptomatic disease, with 53% and 27% of
patients having WHO stages 3 and 4 disease, respectively.
During follow-up, only 7 (1%) patients switched to the
second-line drug regimen.
Virological and CD4 cell responses to ART
Virological responses to treatment were excellent with
viral load suppressed <400 copies/ml in ≥ 94% of patients
at each of the follow-up time-points (Table 1). As a result,
the frequency distribution of blood CD4 cell counts
within the cohort shifted markedly from baseline over 48
weeks of treatment (Fig. 1). Whereas the proportion of
individuals with CD4 cell counts <100 cells/µl was 51% at
baseline, this proportion decreased to only 4% by week 48
of treatment. The median CD4 cell count increased almost
3-fold from baseline, reaching 261 cells/µl after 48 weeks
ART (Table 1).
The rate of CD4 cell count increase in the first 16 week
period greatly exceeded the rates in both the 16–32 week
and 32–48 week intervals, but the rates did not differ
comparing the latter two intervals. Thus, the pattern of
CD4 cell count increase was divided into 2 phases: a ra–
pid phase 1 (0–16 weeks; median = 25.5 cells/µl/month)
and a slower phase 2 (16–48 weeks; median = 7.7 cells/µl/
month).
Baseline characteristics and rates of CD4 cell count change
in phase 1 and phase 2 did not differ when comparing the
results of analyses of all eligible patients with those
restricted to subjects who had data for every time-point (n
= 292); this was also the case for all subsequent stratified
analyses. Use of data from the larger cohort (n = 596) was
therefore validated.
Effect of baseline CD4 cell count on rates of CD4 cell 
increases
Rates of phase 1 CD4 cell increase were similar across all
CD4 cell count strata (Figure 2). Subsequent multivariate
analysis found that baseline plasma viral load was the sin-
gle factor independently associated with phase 1 CD4 cell
recovery (Table 2). This association was strong; among
Graphs showing the frequency distribution of absolute blood CD4 cell counts (a) at bas line (n = 596) and ( ) after 48 weeks (n = 311) of antiretroviral eatme tFigure 1
Graphs showing the frequency distribution of absolute blood 
CD4 cell counts (a) at baseline (n = 596) and (b) after 48 
weeks (n = 311) of antiretroviral treatment. Smoothed 
curves have been fitted.
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those with a baseline viral load <5 log10 copies/ml the
phase 1 CD4 cell slope was 21.3 cells/µl/month compared
to 31.0 cells/µl/month among those with baseline viral
load of >5 log10 copies/ml (P < 0.001).
Contrary to our initial hypothesis, the rate of phase 2 CD4
cell increase was greater among those with a baseline CD4
cell count <50 cells/µl compared to those with higher
baseline counts (Figure 2). This association was highly sig-
nificant in multivariate analysis (Table 2). The rate of
phase 2 CD4 cell increase was also greater among younger
compared to older patients (Figure 3). Multivariate analy-
sis confirmed that both low baseline CD4 cell count and
younger age were the only baseline characteristics that
were significantly associated with higher rates of phase 2
CD4 cell recovery (Table 2).
In the multivariate model predicting rates of phase 2 CD4
cell increase, factors associated with the response to ART
during the first 16 weeks were also included. A lower rate
of phase 1 CD4 cell increase and full suppression of viral
load at 16 weeks were both strongly associated with
greater rate of phase 2 CD4 cell increase. Viral load sup-
pression <400 copies/ml at 16 weeks was associated with
a subsequent rate of CD4 cell increase of 6.8 cells/µl/
month compared to 0.7 cells/µl/month among those
whose viral load remained >400 copies/ml (P < 0.001).
Baseline CD4 cell count and risk of immunological non-
response
We next examined whether baseline CD4 cell count was a
risk factor associated with immunological non-response
(defined as a CD4 cell increase of <50 cells/µl at 48
weeks). Among those followed to 48 weeks (n = 311), the
blood CD4 cell count increased by <50 cells/µl among 30
(9.7%) patients; of these, the viral load was suppressed
<50 copies/ml among 22 patients, representing a treat-
ment discordance rate of 7%. Contrary to our initial
hypothesis, low baseline CD4 cell counts were not associ-
ated with increased risk of immunological non-response.
Table 1: Changes in blood CD4 cell counts and plasma viral load during ART.
Baseline Week 16 Week 32 Week 48
No. of patients 596 596 404 311
Virological Response
Median VL 75,858 <50 <50 <50
Number (%) patients wilh VL ≥ 400 585 (98) 31 (5) 26 (6) 18(6)
Number (%) patients with VL ≥ 50 591 (99) 117 (20) 74 (18) 54 (17)
CD4 Cell Count Response
Median (IQR) CD4 cell count (cells/µl) 97 (50–153) 199 (140,314) 226 (162, 314) 261 (193, 363)
Median (IQR) CD4 cell slope in preceding interval (cells/µl/month) - 25.5 (12.7, 42.9) 7.5 (-4.6, 19.8) 7.9 (-3.0, 20.0)
VL = viral load (copies/ml)
Table 2: Multiple linear regression models estimating the average change in CD4 cell count per month (CD4 slope). Separate models 
analyse the first (0 – 16 weeks) and second (16 – 48 weeks) phases of immune recovery during ART.
Phase 1 (0–16 weeks) CD4 slope (n = 596) Phase 2 (16–48 weeks) CD4 slope (n = 311)1
Mean (95% CI) P value Mean (95% CI) P value
Age (years) <30 1.0 1.0
30–39 -2,27 (-6.71,2.17) 0.32 -2.18 (-5.98, 1.63) 0.26
>40 -2.17 (-7.87, 3.54) 0.46 -7.31 (-12.11, -2. 50) 0.003
Sex Female 1.0 1.0
Male -3.60 (-8.22, 1.02) 0.13 -0.94 (-4.98, 3.10) 0.65
Baseline CD4 coimt (cells/µl) >150 1.0 1.0
100–149 3.85 (-1.63, 9.33) 0,17 -2.17 (-7.09, 2.76) 0.39
50–99 3.53 (-1.84, 8.91) 0.20 0.93 (-4.22, 6.08) 0.72
<50 2.34 (-3.31, 7.98) 0.42 8.55 (2.39, 14.71) 0.007
WHO clinical stage 1 & 2 1.0 1.0
3 1.79 (-3.33, 6.91) 0.49 -0.70 (-5.40, 4.00) 0.77
4 0.55 (-5.39, 6.49) 0.86 -1.76 (-6.93, 3.41) 0.50
Baseline viral load (copies/ml) <5 log10 1.0 1.0
>5 log10 11.14 (7.10, 15.18) <0.001 2.21 (-1.37, 5.80) 0.23
1 The Phase 2 model included as covariates all variables shown, as well the phase 1 CD4 cell slope, the CD4 cell count at 16 weeks and the viral load 
at 16 weeks (see text).
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Among patients with baseline CD4 cell counts of <50, 50–
99, 100–149 and 150 cells/µl, the proportions of patients
who were immunological non-responders were 5%, 4%,
11% and 19%, respectively. Furthermore, in multivariate
analyses, an increment of <50 cells/µl was independently
associated with higher baseline CD4 cell count as well as
older age, lower baseline viral load, and a viral load >400
copies/ml at any follow-up time-point (Table 3).
Baseline CD4 cell count and failure to attain a CD4 cell 
count of ≥ 200 cells/µl
We next determined factors associated with failure to
attain an absolute CD4 cell count of 200 cells/µl at 48
weeks. Although patients with a baseline CD4 cell count
<50 cells/µl had similar rates of phase 1 CD4 cell recovery
and greater rates of phase 2 CD4 cell recovery compared
to those with higher baseline counts, such patients never-
theless had a reduced likelihood of attaining a CD4 cell
count of 200 cells/µl at 48 weeks (Table 3). The propor-
tions of patients with baseline CD4 cell counts of <50,
50–99, 100–149 and 150 cells/µl who failed to attain a
CD4 cell count of 200 cells/µl at 48 weeks were 49%,
35%, 18%, and 9%, respectively. Failure to attain 200
cells/µl was also significantly associated with older age,
lower baseline plasma viral load, and a viral load >400
copies/ml at any follow-up time-point (Table 3).
Super-responders
Of 311 patients studied out to 48 weeks, 21 (6.8%)
achieved an absolute CD4 cell count of >500 cells/µl.
These super-responders were principally characterised by
age <40 years and by all having follow-up viral loads per-
sistently suppressed <50 copies/ml and a CD4 cell count
of 150 cells/µl after 16 weeks of ART. This group of
patients had a wide distribution of baseline CD4 cell
counts, and included among them were 4 (19%) who had
baseline CD4 cell counts of <50 cells/µl. Thus, a low base-
line CD4 cell count did not preclude patients from having
an excellent immunological response.
Discussion
To our knowledge this is the first analysis to examine the
determinants of CD4 cell count recovery among patients
receiving ART in resource limited settings. These data indi-
cate that those with baseline CD4 cell counts <50 cells/µl
had similar rates of phase 1 CD4 recovery (0–16 weeks)
and greater rates of phase 2 recovery (16–48 weeks) com-
pared to rates among those with higher baseline CD4 cell
counts. Moreover, those with the lowest baseline counts
Graph showing the median CD4 cell counts at baseline and during ART stra ified by geFigure 3
Graph showing the median CD4 cell counts at baseline and 
during ART stratified by age. Below the graph, the median 
(IQR) rates of CD4 cell increase (cells/µl/month) are given 
for phase 1 (0 – 16 weeks) and phase 2 (16–48 weeks) of 
immune recovery.
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during ART stratified by baseline CD4 cell count. Below the 
graph, the median (IQR) rates of CD4 cell increase (cells/µl/
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were least likely to be immunological non-responders to
ART. Despite these observations, those with baseline CD4
cell counts <50 cells/µl were nevertheless least likely to
attain a CD4 cell count 200 cells/µl at 48 weeks. Taken
together, these results suggest that although patients with
very low baseline CD4 cell counts retain capacity for sim-
ilar or slightly greater rates of CD4 cell count recovery
compared to those with higher counts, they are neverthe-
less likely to require a longer period of time to attain a
CD4 cell count threshold of 200 cells/µl. Thus, a pro-
longed period below a 'safe' CD4 cell count threshold
rather than a diminished rate of immunological recovery
is likely to underlie the high rates of morbidity and mor-
tality observed among those with advanced disease during
the early months of ART [4,5,8].
The findings of this analysis are strengthened by the rela-
tively homogeneous study population receiving treatment
at a single facility using standardised clinical protocols.
Patients were all ART-naïve and received a standard triple-
drug regimen with uniform follow-up time points. Qual-
ity-assured laboratory assays were all performed in a sin-
gle nationally accredited laboratory. In contrast, previous
studies of the determinants of CD4 cell count recovery
have examined heterogeneous study populations in mul-
tiple centres and used diverse treatment regimens. Moreo-
ver, these studies included many patients with prior ART
exposure [20-22] and some included only those who
maintained suppression of plasma HIV load [9,23,24].
Our patient population was treated under the government
ART roll-out programme and data are therefore likely to
be generalisable to other ART programmes in sub-Saharan
Africa. Our study is limited to analysis of CD4 cell recov-
ery during the first year of ART and long-term outcomes
and their sustainability remain to be determined. Moreo-
ver, in the present analysis we have examined recovery of
CD4 cell counts but not CD4 cell functional responses.
The immunological response to ART among those with
low CD4 cell counts was excellent with the proportion of
patients with a CD4 cell count <100 cells/µl decreasing
from 51% at baseline to just 4% at 48 weeks. However,
our most important finding was that in multivariate anal-
ysis baseline CD4 cell counts <50 cells/µl were independ-
ently associated with similar rates of phase 1 CD4 cell
recovery and greater rates of phase 2 CD4 cell recovery
compared to individuals with higher baseline CD4 cell
counts. This has not been clearly highlighted in previous
publications from Europe and North America although
comparison of our data with previous studies is difficult
in view of differing cohort compositions. However, this
overall observation is consistent with the findings of Ben-
nett et al.[21], and Le Moing et al. showed a similar but
non-significant trend when comparing patients with base-
line CD4 cell counts <200 cells/µl with those with higher
counts [20]. Kaufmann et al. found that CD4 cell increases
in the first year of ART were similar comparing those with
baseline counts <100 cells/µl with those with counts 100–
199 cells/µl [22].
Survival bias could potentially have affected our findings.
We have previously shown in this cohort that patients
with the lowest baseline CD4 cell counts had a higher risk
of death [5] and immunological non-responders or poor
Table 3: Results of logistic regression models predicting overall change in blood CD4 cell count during ART. Responses are defined as 
either (i) the risk of immunological non-response (an increase of <50 cells/µl) or (ii) failure to attain an absolute CD4 cell count of ≥ 200 
cells/µl after 48 weeks ART.
Risk of immumological non-respouse at 48 
weeks
Risk of failure to attain CD4 cell count of ≥ 
200 cells/µl at 48 weeks
OR (95% CI) P value OR (95% CI) P value
Age (years) <30 1.0 1.0
30–39 3.15 (1.09, 9.15) 0.035 1.34 (0.66, 2.72) 0.41
>40 3.88 (1.13, 13.39) 0.032 3.52 (1.55, 7.99) 0.003
Sex Female 1.0
Male 0.42 (0.13, 1.39) 0.16 1.73 (0.90, 3.35) 0.10
Baseline CD4 count >150 1.0 1.0
100–149 0.63 (0.23, 1.72) 0.37 2.49 (0.89, 6.96) 0.08
50–99 0.18 (0.05 0.70) 0.013 5.97 (2.29, 15.58) <0.001
<50 0.18 (0.05, 0.72) 0.016 12.11 (4.43, 33.14) <0.001
WHO clinical stage 1 & 2 1.0 1.0
3 1.12 (0.37, 3.40) 0.84 1.32 (0.54, 3.26) 0.54
4 2.11 (0.63, 7.03) 0.22 1.19 (0.45, 3.17) 0.72
Baseline viral load <5 log10 1.0 1.0
>5 log10 0.21 (0.07, 0.66) 0.008 0.47 (0.26, 0.86) 0.014
Follow-up viral load <400 all visits 1.0 1.0
>400 any visit 4.25 (1.30, 13.87) 0.017 3.00 (1.14, 7.90) 0.026
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responders may have a greater mortality risk, leading to a
survivor effect. However, we were careful to ensure that
rates of CD4 cell recovery in the CD4 cell strata did not
differ when comparing analyses of the whole cohort with
those for whom data points were available at every time-
point. Secondly, WHO clinical stage of disease is the
strongest predictor of death in this cohort [5] and yet this
variable was not associated with CD4 cell responses.
Thirdly, the majority of deaths occurred in the first few
weeks of ART among those whose disease was simply too
far advanced; such deaths probably do not reflect a lack of
immunological response to ART. Finally, we have previ-
ously reported that over 20% of early deaths in this cohort
are due to immune reconstitution disease [5,25]; such
deaths typically occur among those with low baseline
CD4 cell counts and good CD4 cell recovery. These deaths
would tend to cause exactly the opposite bias. Thus,
although an important consideration, we do not think
that survival bias had an overall dominant effect.
We have previously shown that low baseline CD4 count at
entry to an ART programme was associated with increased
risks of tuberculosis and of mortality during the first year
of ART [5,8]. Results from the present study suggest that
these increased risks are likely to reflect an increased
period of time required for such patients to achieve a 'safe'
level of immune function rather than reflecting impaired
rates of immune recovery and this is consistent with the
findings of a study from Spain with longer term follow-up
[11]. More recently we have found that risk of mortality
and risk of incident tuberculosis is strongly associated
with the current CD4 cell count during ART rather than
the baseline count (unpublished data). Thus, if patients
with profound baseline CD4 lymphocytopenia survive
the initial few months of treatment and achieve full viral
load suppression, then high rates of immune recovery are
likely to result in a better prognosis that might have been
anticipated.
Rates of phase 1 and phase 2 CD4 cell increase were sim-
ilar in magnitude to those previously reported from high-
income countries [9,20]. The rapid phase 1 CD4 cell
recovery was strongly associated with baseline viral load
as described previously [20,21]; patients with viral loads
>105 log10 copies/ml had 11-fold greater CD4 count
increases than those with lower viral loads. Immune dys-
regulation and immune cell activation promote sequestra-
tion of CD4+CD45Ro+ memory T cells in lymphoid tissue;
suppression of viral replication then triggers rapid redistri-
bution of this cell pool and a reduction in apoptotic cell
death during the initial weeks of ART [26,27]. A positive
correlation between the plasma viral load and the degree
of cell sequestration may provide a possible mechanism
underlying the observation that those with the highest
viral loads have the greatest initial CD4 cell increment.
The fact that patients with profound CD4 lymphocytope-
nia have good immunological recovery during ART is
likely to be important in the pathogenesis of immune
reconstitution disease associated with Mycobacterium
tuberculosis[28], Cryptococcus neoformans[25] that is fre-
quently observed in this patient population.
Greater phase 2 CD4 cell recovery was strongly associated
with age as reported elsewhere [9,24]. Sustained suppres-
sion of viral replication is also critical to second phase
recovery [20,21] and we confirmed that viral load at 16
weeks was a strong independent predictor of subsequent
immunological recovery. Ten per cent of patients were
immunological non-responders (CD4 cell increment <50
cells/µl at 48 weeks) and 7% of patients had discordant
responses, having immunological non-response despite a
fully suppressed viral load. These rates are much lower
than those reported in previous series from industrialised
countries [14,29], possibly because our study only
included antiretroviral-naïve patients, rates of HIV pri-
mary drug resistance in this setting are likely to be low,
and because rates of treatment adherence in our cohort
are very high. However, those with CD4 cell counts <50
cells/µl were least likely to be immunological non-
responders. Moreover, 19% of 'super-responders' had
baseline CD4 cell counts <50 cells/µl, indicating that a
very low baseline CD4 cell count does not preclude an
excellent CD4 cell count response to ART.
Conclusion
Patients with the lowest CD4 counts in this setting do not
have diminished capacity for immune recovery. Although
patients with low baseline CD4 counts have increased risk
of acute morbidity and mortality, if such patients survive
the initial months of ART and fully suppress the viral load,
their chances of immunological recovery are good during
the first year. Future studies are required to determine the
long-term prospects for immune recovery among patients
treated in ART programmes in sub-Saharan Africa.
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